The invention relates to novel indolocarbazole derivatives, eg. of formula III
(wherein:
R1 is selected from the group consisting of halogen, CH2OCONHR14 and NHCO2R14;
R2 is selected from the group consisting of hydrogen and halogen;
X is selected from the group consisting of CO2CH3, CH2OH and CONHR15;
R14 represents lower alkyl; and
R15 is hydrogen, hydroxy substituted lower alkyl, or aryl; with the proviso that when R1 = halogen and R2 = hydrogen, X is neither CO2CH3 nor CH2OH; and with the proviso that when R1 = R2 = halogen, X is not CO2CH3; and with the proviso that when R1 = R2 = Br, X is not CONHC6H5)
which are useful in the treatment of pathological conditions of the prostate gland.
本发明涉及新型
吲哚咔唑衍
生物,如式 III
(其中
R1 选自由卤素、CH2OCONHR14 和 NHCO2R14 组成的组;
R2 选自氢和卤素组成的组;
X 选自 CO2CH3、CH2OH 和 CONHR15 组成的组;
R14 代表低级烷基;和
R15 是氢、羟基取代的低级烷基或芳基;但有以下限制条件:当 R1 = 卤素和 R2 = 氢时,X 既不是 CO2CH3 也不是 CH2OH;当 R1 = R2 = 卤素时,X 不是 CO2CH3;当 R1 = R2 = Br 时,X 不是 CONHC6H5)
可用于治疗前列腺病变。